COMBINATION OF DNA PLASMID VACCINE VB10.NEO AND BEMPEGALDESLEUKIN (NKTR-214) INDUCES STRONG NEOANTIGEN-SPECIFIC T CELL RESPONSES AND SUSTAINED TUMOR REGRESSION IN PRECLINICAL MODELS